%0 Journal Article %A TOSHIO INUI %A KENTARO KUBO %A DAISUKE KUCHIIKE %A YOSHIHIRO UTO %A TAKAHITO NISHIKATA %A NORIHIRO SAKAMOTO %A MARTIN METTE %T Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports %D 2015 %J Anticancer Research %P 4545-4549 %V 35 %N 8 %X Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy. Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects. Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases. %U https://ar.iiarjournals.org/content/anticanres/35/8/4545.full.pdf